According to filings with the U.S. Securities and Exchange Commission, Actuate Therapeutics is raising up to $5,000,000.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Daniel Schmitt played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Actuate Therapeutics
Actuate aims to give patients with hard-to-treat cancers the opportunity to live longer and better through a best-in-class agent with the potential capacity to slow, stop, or shrink tumors, with minimal adverse effects. Actuates lead drug, elraglusib (a novel GSK-3 inhibitor), targets multiple molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy. Elraglusib is also emerging as a mediator of anti-tumor immunity through the inhibition of multiple immune checkpoints and the regulation of immune cell function. Our focus on the GSK-3, glycogen synthase kinase-3 enzyme has led to the therapeutic candidate elraglusib, formerly known as 9-ING-41. Elraglusib has shown tremendous potential in the treatment of many different cancers when used alone or in combination with other types of cancer therapies, including chemotherapy and immune modulators such as checkpoint inhibitors. It is our belief that this versatile agent will improve clinical outcomes for patients suffering from advanced, hard-to-treat cancers.

To learn more about Actuate Therapeutics, visit http://actuatetherapeutics.com/

Contact:
Daniel Schmitt, President and Chief Executive Officer
847-986-4190
https://www.linkedin.com/in/dan-schmitt-0094b05/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.